You are here

Zubsolv (Buprenorphine/Naloxone) Accepted for FDA Review

Approval decision expected in July 2013 (Nov. 19)

The FDA has agreed to review the New Drug Application (NDA) for Zubsolv (buprenorphine and naloxone, Orexo). The agency has set a Prescription Drug User Fee Act (PDUFA) action date of July 6, 2013.

Zubsolv is a sublingual formulation of the semi-synthetic opioid buprenorphine and the opioid inverse agonist naloxone. If approved, the drug is expected to be launched in September 2013. It has been designed to offer an alternative to Suboxone (buprenorphine and naloxone, Reckitt Benckiser) — currently the leading product in the U.S. for the treatment of opioid dependence.

More than 2 million Americans are dependent on opioids, with related healthcare costs totaling an estimated $25 billion. The U.S. opioid dependence market currently served by Suboxone is estimated to reach sales of $1.5 billion in 2012 and to show steady growth of more than 15% per year thereafter.

Source: Orexo; November 19, 2012.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress